MiRNA and Potential Prognostic Value in Non-Smoking Females with Lung Adenocarcinoma by High-Throughput Sequencing

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Behrend SJ, Giotopoulou GA, Spella M, Stathopoulos GT. A role for club cells in smoking-associated lung adenocarcinoma. Eur Respir Rev. 2021;30(162):210122. doi:10.1183/16000617.0122-2021
   PubMed Web of Science ®Google Scholar
• Liang SK, Chien LH, Chang GC, et al. Programmed death ligand 2 gene polymorphisms are associated with lung adenocarcinoma risk in female never-smokers. Front Oncol. 2021;11:753788. doi:10.3389/fonc.2021.753788
   PubMed Web of Science ®Google Scholar
• Shi K, Li N, Yang M, Li W. Identification of key genes and pathways in female lung cancer patients who never smoked by a bioinformatics analysis. J Cancer. 2019;10(1):51–60. doi:10.7150/jca.26908
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Z, Xu K, Wei S, Li L, Wang L. Exploration of estrogen receptor-associated hub genes and potential molecular mechanisms in non-smoking females with lung adenocarcinoma using integrated bioinformatics analysis. Oncol Lett. 2019;18(5):4605–4612. doi:10.3892/ol.2019.10845
   PubMed Web of Science ®Google Scholar
• Ziebarth NR. Lung cancer risk perception biases. Prev Med. 2018;110:16–23. doi:10.1016/j.ypmed.2018.01.020
   PubMed Web of Science ®Google Scholar
• Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12–23. doi:10.1016/j.critrevonc.2015.10.003
   PubMed Web of Science ®Google Scholar
• Ganju A, Khan S, Hafeez BB, et al. miRNA nanotherapeutics for cancer. Drug Discov Today. 2017;22(2):424–432. doi:10.1016/j.drudis.2016.10.014
   PubMed Web of Science ®Google Scholar
• Nie H, Xie X, Zhang D, et al. Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer. Nanoscale. 2020;12(2):877–887. doi:10.1039/c9nr09011h
   PubMed Web of Science ®Google Scholar
• Hong W, Xue M, Jiang J, Zhang Y, Gao X. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39(1):149. doi:10.1186/s13046-020-01648-1
   PubMed Web of Science ®Google Scholar
• Jiang C, Hu X, Alattar M, Zhao H. miRNA expression profiles associated with diagnosis and prognosis in lung cancer. Expert Rev Anticancer Ther. 2014;14(4):453–461. doi:10.1586/14737140.2013.870037
   PubMed Web of Science ®Google Scholar
• Cheng Y, Yang S, Shen B, et al. Molecular characterization of lung cancer: a two-miRNA prognostic signature based on cancer stem-like cells related genes. J Cell Biochem. 2020;121(4):2889–2900. doi:10.1002/jcb.29525
   PubMed Web of Science ®Google Scholar
• Asakawa Y, Okabe A, Fukuyo M, et al. Epstein-Barr virus-positive gastric cancer involves enhancer activation through activating transcription factor 3. Cancer Sci. 2020;111(5):1818–1828. doi:10.1111/cas.14370
   PubMed Web of Science ®Google Scholar
• Zeng F, Luo L, Li D, Guo J, Guo M. KPNA2 interaction with CBX8 contributes to the development and progression of bladder cancer by mediating the PRDM1/c-FOS pathway. J Transl Med. 2021;19(1):112. doi:10.1186/s12967-021-02709-5
   PubMed Web of Science ®Google Scholar
• Sun Y, Li W, Li X, Zheng H, Qiu Y, Yang H. Oncogenic role of karyopherin α2 (KPNA2) in human tumors: a pan-cancer analysis. Comput Biol Med. 2021;139:104955. doi:10.1016/j.compbiomed.2021.104955
   PubMed Web of Science ®Google Scholar
• Li H, Yuan H. MiR-1297 negatively regulates metabolic reprogramming in glioblastoma via repressing KPNA2. Hum Cell. 2020;33(3):619–629. doi:10.1007/s13577-019-00316-7
   PubMed Web of Science ®Google Scholar
• Putra V, Hulme AJ, Tee AE, et al. The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma. Mol Oncol. 2021;15(4):1162–1179. doi:10.1002/1878-0261.12906
   PubMed Web of Science ®Google Scholar
• Huang RH, Yang WK, Wu CM, Yeh CM, Sung WW. Over-expression of CEP55 predicts favorable prognosis in colorectal cancer patients with lymph node involvement. Anticancer Res. 2021;41(1):543–547. doi:10.21873/anticanres.14806
   PubMed Web of Science ®Google Scholar
• Feng J, Guo Y, Li Y, et al. Tumor promoting effects of circRNA_001287 on renal cell carcinoma through miR-144-targeted CEP55. J Exp Clin Cancer Res. 2020;39(1):269. doi:10.1186/s13046-020-01744-2
   PubMed Web of Science ®Google Scholar
• Li M, Liu Y, Jiang X, et al. Inhibition of miR-144-3p exacerbates non-small cell lung cancer progression by targeting CEP55. Acta Biochim Biophys Sin. 2021;53(10):1398–1407. doi:10.1093/abbs/gmab118
   Google Scholar
• Banerjee R, Liu M, Bellile E, et al. Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab. Mol Ther. 2021. doi:10.1016/j.ymthe.2021.06.009
   Web of Science ®Google Scholar
• Chen X, Lu Y, Yu H, et al. Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene. Cell Cycle. 2021;1–18. doi:10.1080/15384101.2021.1982494
   Web of Science ®Google Scholar
• Zeng L, Liu YM, Yang N, Zhang T, Xie H. Hsa_circRNA_100146 promotes prostate cancer progression by upregulating TRIP13 via Sponging miR-615-5p. Front Mol Biosci. 2021;8:693477. doi:10.3389/fmolb.2021.693477
   PubMed Web of Science ®Google Scholar
• Chen F, Liu L, Wang S. Long non-coding RNA NORAD exhaustion represses prostate cancer progression through inhibiting TRIP13 expression via competitively binding to miR-495-3p. Cancer Cell Int. 2020;20:323. doi:10.1186/s12935-020-01371-z
   PubMed Web of Science ®Google Scholar
• Li X, Jiao M, Hu J, et al. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4. Prostate. 2020;80(9):674–686. doi:10.1002/pros.23979
   PubMed Web of Science ®Google Scholar
• Xu Q, Xu Z, Zhu K, Lin J, Ye B. LINC00346 Sponges miR-30c-2-3p to promote the development of lung adenocarcinoma by targeting MYBL2 and regulating CELL CYCLE signaling pathway. Front Oncol. 2021;11:687208. doi:10.3389/fonc.2021.687208
   PubMed Web of Science ®Google Scholar
• Su X, Lang C, Luan A, Zhao P. MiR-200a promotes proliferation of cervical cancer cells by regulating HIF-1α/VEGF signaling pathway. J BUON. 2020;25(4):1935–1940.
   PubMed Web of Science ®Google Scholar
• Huang Y, Bao T, Li Z, Ji G, Zhang L. Function of miR-200a in proliferation and apoptosis of non-small cell lung cancer cells. Oncol Lett. 2020;20(2):1256–1262. doi:10.3892/ol.2020.11649
   PubMed Web of Science ®Google Scholar
• Wang T, Tang X, Liu Y. LncRNA-ATB promotes apoptosis of non-small cell lung cancer cells through MiR-200a/β-Catenin. J BUON. 2019;24(6):2280–2286.
   PubMed Web of Science ®Google Scholar
• Xiang J, Wu Y, Li DS, et al. miR-584 suppresses invasion and cell migration of thyroid carcinoma by regulating the target oncogene ROCK1. Oncol Res. 2015;38(9):436–440. doi:10.1159/000438967
   Web of Science ®Google Scholar
• Ebrahimi Ghahnavieh L, Tabatabaeian H, Ebrahimi Ghahnavieh Z, et al. Fluctuating expression of miR-584 in primary and high-grade gastric cancer. BMC Cancer. 2020;20(1):621. doi:10.1186/s12885-020-07116-5
   PubMed Web of Science ®Google Scholar
• Siriwardhana C, Khadka VS, Chen JJ, Deng Y. Development of a miRNA-seq based prognostic signature in lung adenocarcinoma. BMC Cancer. 2019;19(1):34. doi:10.1186/s12885-018-5206-8
   PubMedGoogle Scholar
• Zhang Y, Roth JA, Yu H, et al. A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer. Carcinogenesis. 2019;40(5):643–650. doi:10.1093/carcin/bgy132
   PubMed Web of Science ®Google Scholar